Epizyme prices IPO at $15, the high end of the range


Shutterstock photo

Epizyme, a biotech developing therapeutics for patients with genetically defined cancers, raised $77 million by offering 5.1 million shares at $15, the high end of the range of $13 to $15. Epizyme plans to list on the NASDAQ under the symbol EPZM. Epizyme initially filed confidentially on 3/22/2013. Citi, Cowen & Company and Leerink Swann acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com